COMORBIDITIES IN PATIENTS WITH PARKINSON'S DISEASE
DOI:
https://doi.org/10.52692/1857-0011.2021.3-71.25Keywords:
Parkinson’s disease, non-motor symptoms, anemia, cancer, comorbidities, depression, diabetesAbstract
A wide spectrum of comorbidities has been associated with Parkinson’s disease (PD), a progressive neurodegenerative disease that affects more than seven million people worldwide. Emerging evidence indicates that chronic diseases including diabetes, depression, anemia and cancer may be implicated in the pathogenesis and progression of PD. Recent epidemiological studies suggest that some of these comorbidities may increase the risk of BP and may precede the onset of motor symptoms. However, the mechanisms underlying these comorbidities remain elusive.References
Hoehn, M. M., and Yahr, M. D. (1967). Parkinsonism: onset, progression, and mortality. Neurology 17, 427–442. doi: 10.1212/wnl.17.5.427
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., et al. (2017). Parkinson disease. Nat. Rev. Dis. Primers 3:17013. doi: 10.1038/nrdp.2017.13
Park, A., and Stacy, M. (2009). Non-motor symptoms in Parkinson’s disease. J. Neurol. 256, 293–298. doi:10.1007/s00415-009-5240-1
Visanji, N., and Marras, C. (2015). The relevance of pre-motor symptoms in Parkinson’s disease.Expert Rev. Neurother. 15, 1205–1217. doi:10.1586/14737175.2015.1083423
Trojano, L., and Papagno, C. (2017). Cognitive and behavioral disorders in Parkinson’s disease: an update.II: behavioral disorders. Neurol. Sci. doi: 10.1007/s10072-017-3155-7 [Epub ahead of print].
Schapira, A. H. V., Chaudhuri, K. R., and Jenner,P. (2017). Non-motor features of Parkinson disease. Nat.Rev. Neurosci. 18:509. doi: 10.1038/nrn.2017.91
Fenelon, G., Mahieux, F., Huon, R., and Ziegler,M. (2000). Hallucinations in Parkinson’s disease: prevalence,phenomenology and risk factors. Brain 123, 733–745. doi: 10.1093/brain/123.4.733
Burghaus, L., Eggers, C., Timmermann, L.,Fink, G. R., and Diederich, N. J. (2012). Hallucinations in neurodegenerative diseases. CNS Neurosci. Ther. 18,149–159. doi: 10.1111/j.1755-5949.2011.00247.x
Goldman, J. G., Stebbins, G. T., Leung, V., Tilley,B. C., and Goetz, C. G. (2014). Relationships among cognitive impairment, sleep, and fatigue in Parkinson’s diseaseusing the MDS-UPDRS. Parkinsonism Relat. Disord.20, 1135–1139. doi: 10.1016/j.parkreldis.2014.08.001
Papagno, C., and Trojano, L. (2017). Cognitive and behavioral disorders in Parkinson’s disease: an update.I: cognitive impairments. Neurol. Sci. doi: 10.1007/s10072-017-3154-8 [Epub ahead of print]
Sprenger, F. S., Seppi, K., Djamshidian, A., Reiter,E., Nocker, M., Mair, K., et al. (2015). Nonmotor symptoms in subjects without evidence of dopaminergic deficits.Mov. Disord. 30, 976–981. doi: 10.1002/mds.26204
Leibson, C. L., Maraganore, D. M., Bower, J. H.,Ransom, J. E., O’Brien, P. C., and Rocca, W. A. (2006).Comorbid conditions associated with Parkinson’s disease:a population-based study. Mov. Disord. 21, 446–455. doi:10.1002/mds.20685
Santos García, D., Suárez Castro, E., Expósito, I.,De Deus, T., Tuñas, C., Aneiros, A., et al. (2017). Comorbid conditions associated with Parkinson’s disease: a longitudinal and comparative study with Alzheimer disease and control subjects. J. Neurol. Sci. 373, 210–215. doi:10.1016/j.jns.2016. 12.046
Akter, K., Lanza, E. A., Martin, S. A., Myronyuk,N., Rua, M., and Raffa, R. B. (2011). Diabetes mellitus and Alzheimer’s disease: shared pathology and treatment? Br. J. Clin. Pharmacol. 71, 365–376. doi: 10.1111/j.1365-2125. 2010.03830.x
Kioumourtzoglou, M. A., Rotem, R. S., Seals, R.M., Gredal, O., Hansen, J., and Weisskopf, M. G. (2015).Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA Neurol.72,905–911. doi: 10.1001/jamaneurol.2015.0910
Santiago, J. A., and Potashkin, J. A. (2013b).Shared dysregulated pathways lead to Parkinson’s disease and diabetes. Trends Mol. Med. 19, 176–186. doi:10.1016/j. molmed.2013.01.002
Cereda, E., Barichella, M., Cassani, E., Caccialanza,R., and Pezzoli, G. (2012). Clinical features of Parkinson disease when onset of diabetes came first: a case-control study. Neurology 78, 1507–1511. doi: 10.1212/WNL.0b013e3182553cc9
Bosco, D., Plastino, M., Cristiano, D., Colica,C., Ermio, C., De Bartolo, M., et al. (2012). Dementia is associated with insulin resistance in patients with Parkinson’s disease. J. Neurol. Sci. 315, 39–43. doi: 10.1016/j.jns.2011.12.008
Geng, X., Lou, H., Wang, J., Li, L., Swanson, A.L., Sun, M., et al. (2011). α-Synuclein binds the K(ATP)channel at insulin-secretory granules and inhibits insulinsecretion. Am. J. Physiol. Endocrinol. Metab. 300, E276–E286. doi: 10.1152/ajpendo.00262.2010
Santiago, J. A., and Potashkin, J. A. (2013a). Integrative network analysis unveils convergent molecular pathways in Parkinson’s disease and diabetes. PLoS One 8:e83940. doi: 10.1371/journal.pone.0083940
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Kahan, J., Ell, P., et al. (2014). Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s disease. J. Parkinsons Dis. 4, 337–344. doi: 10.3233/JPD-140364
Aarsland, D., Påhlhagen, S., Ballard, C. G., Ehrt,U., and Svenningsson, P. (2011). Depression in Parkinson disease—epidemiology, mechanisms and management. Nat. Rev. Neurol. 8, 35–47. doi: 10.1038/nrneurol.2011.189
Balestrino, R., and Martinez-Martin, P. (2017). Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson’s disease. J. Neurol. Sci. 373, 173–178. doi: 10.1016/j.jns.2016.12.060
Schrag, A., Barone, P., Brown, R. G., Leentjens,A. F., Mcdonald, W. M., Starkstein, S., et al. (2007). Depression rating scales in Parkinson’s disease: critique and recommendations. Mov. Disord. 22, 1077–1092. doi:10.1002/mds. 21333
Nilsson, F. M., Kessing, L. V., Sørensen, T. M., Andersen, P. K., and Bolwig, T. G. (2002). Major depressive disorder in Parkinson’s disease: a register-based study. Acta Psychiatr. Scand. 106, 202–211. doi: 10.1034/j.1600-0447.2002.02229.x
Mayeux, R. (1990). The ‘‘serotonin hypothesis’’ for depression in Parkinson’s disease. Adv. Neurol. 53,163–166
Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A., Jansen Steur, E. N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 24, 197–211. doi: 10.1016/S0197-4580(02)00065-934 Buletinul AȘM
Leentjens, A. F. (2015). Parkinson disease: depression-risk factor or early symptom in Parkinson disease? Nat.Rev. Neurol. 11, 432–433. doi: 10.1038/nrneurol. 2015.126
Pessoa Rocha, N., Reis, H. J., Vanden Berghe, P.,and Cirillo, C. (2014). Depression and cognitive impairment in Parkinson’s disease: a role for inflammation and immunomodulation? Neuroimmunomodulation 21, 88–94. doi: 10.1159/000356531
Felger, J. C., Li, Z., Haroon, E., Woolwine, B. J., Jung,M. Y., Hu, X., et al. (2016). Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Mol. Psychiatry 21, 1358–1365. doi:10.1038/mp.2015.168 Fenelon, G., Mahieux, F., Huo
Logroscino, G., Chen, H., Wing, A., and Ascherio, A. (2006). Blood donations, iron stores, and risk of Parkinson’s disease. Mov. Disord. 21, 835–838. doi: 10.1002/mds.20826
Tang, C.-F., Lu, M.-K., Muo, C.-H., Tsai, C.-H.,and Kao, C.-H. (2016). Increased risk of brain tumor in patients with Parkinson’s disease: a nationwide cohort study in Taiwan. Acta Neurol. Scand. 134, 148–153. doi:10.1111/ane.12524
Savica, R., Grossardt, B. R., Carlin, J. M., Icen,M., Bower, J. H., Ahlskog, J. E., et al. (2009). Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study. Neurology 73, 1381–1387. doi:10.1212/WNL. 0b013e3181bd80c1
Feng, D. D., Cai, W., and Chen, X. (2015). The associations between Parkinson’s disease and cancer: the plot thickens. Transl. Neurodegener. 4:20. doi: 10.1186/s40035-015-0043-z
Gao, X., Simon, K. C., Han, J., Schwarzschild, M. A., and Ascherio, A. (2009b). Genetic determinants of hair color and Parkinson’s disease risk. Ann. Neurol. 65, 76–82. doi: 10.1002/ana.21535
Bethge, N., Lothe, R. A., Honne, H., Andresen, K., Trøen, G., Eknæs, M., et al. (2014). Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma. Epigenetics 9, 428–436. doi:10.4161/epi.27554
Farmer, K., Rudyk, C., Prowse, N. A., and Hayley, S. (2015). Hematopoietic cytokines as therapeutic players in early stages Parkinson’s disease. Front. Aging Neurosci. 7:126. doi: 10.3389/fnagi.2015.00126
Bajaj, A., Driver, J. A., and Schernhammer, E. S.(2010). Parkinson’s disease and cancer risk: a systematic review and meta-analysis. Cancer Causes & Control 21,697–707. doi: 10.1007/s10552-009-9497-6
Inzelberg, R., Samuels, Y., Azizi, E., Qutob, N., Inzelberg, L., Domany, E., et al. (2016b). Parkinson disease (PARK) genes are somatically mutated in cutaneous melanoma. Neurol. Genet. 2:e70. doi: 10.1212/NXG.0000000000000070
Yamashita, K., Miyata, H., Makino, T., Masuike,Y., Furukawa, H., Tanaka, K., et al. (2017). High Expression of the mitophagy-related protein pink1 is associated with a poor response to chemotherapy and a poor prognosis
for patients treated with neoadjuvant chemotherapy for esophageal squamous cell carcinoma. Ann. Surg. Oncol. 24, 4025–4032. doi: 10.1245/s10434-017 -6096-8
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
